ClinicalTrials.gg
CompletedNCT01125800Updated Mar 20, 2017Results posted

A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB

A Phase 1/2 interventional study of LDE225 in Medulloblastoma, Rhabdomyosarcoma and Neuroblastoma, sponsored by Novartis Pharmaceuticals. Completed at 14 sites in 6 countries. Open to participants aged 12 Months to 18 Years. Per ClinicalTrials.gov, last updated 2017-03-20.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
76
Allocation
Non-randomized
Ages
12 Months to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 245 studies in Medulloblastoma with a site in United States — 26 open to participants now, 53 under way, 2 of them phase 3. Medulloblastoma · United States.

Enrollment
43rd of 215
76 · median 30
Started
2011
with 4 others
Phase 1/2
22 of 245
3 open now
Registered
116th of 245
by date
Lead sponsor
6 of 245
Novartis Pharmaceuticals

Among the 245 studies in Medulloblastoma with a site in United States, this one is the 43rd largest by enrollment of the 215 interventional ones that give a count, is one of 5 that started in 2011, is one of 22 in phase 1/2, and was the 116th registered.

Medulloblastoma

317 studies on the registry are indexed under Medulloblastoma; 52 are open to participants now.

Browse Medulloblastoma studies →

Open to participants now

26 of the 245 studies in Medulloblastoma with a site in United States are open now. Recruiting first, the newest first:

21 more — sign in →

All 26 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 38 Medulloblastoma studies recruiting now, 4 (11%) set no upper age limit and 32 (84%) stop at 75 or younger; 35 take children under 18; 1 takes healthy volunteers.

This study: 12 Months to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 245 studies in Medulloblastoma with a site in United States, or all of them as a file.
02

Study summary

Phase I dose-escalation study to characterize the safety, tolerability, pharmacokinetics and pharmacodynamics of LDE225 given orally on a daily dosing schedule in children with recurrent or refractory medulloblastoma, or other tumors potentially dependent on Hedgehog signaling pathway.

Phase II study is to assess preliminary efficacy in both adult and pediatric patients with recurrent or refractory MB.

03

Conditions studied

  • Medulloblastoma
  • Rhabdomyosarcoma
  • Neuroblastoma
  • Hepatoblastoma
  • Glioma
  • Astrocytoma

Keywords

  • Recurrent,
  • refractory,
  • medulloblastoma,
  • rhabdomyosarcoma,
  • neuroblastoma,
  • hepatoblastoma,
  • astrocytoma,
  • children,
  • pediatric,
  • hedgehog pathway inhibitor, adult
04

Who can participate

Ages eligible
12 Months to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Phase I - Patients aged ≥12 months and \<18 years, Phase II - Patients ≥12 months
  • Phase I - confirmed diagnosis of medulloblastoma, rhabdomyosarcoma, neuroblastoma, hepatoblastoma, high grade glioma, or osteosarcoma, that has progressed despite treatment with standard therapies, or for which no standard treatments are available (patients with brainstem gliomas are excluded). Phase II - Histologically confirmed diagnosis of recurrent or medulloblastoma with at least one .
  • Performance Status: ≥60% for patients >10 yrs, Lansky ≥50 for patients less than or equal to 10 yrs
  • Protocol-defined renal , liver and bone marrow function
  • Negative pregnancy test before starting study treatment. If of child bearing potential must use 'highly effective' methods of .
  • All patients must consent to provide a tumor sample

Exclusion criteria

Exclusion Criteria:

  • Systemic anti-cancer treatment within 2 weeks prior to first dose (6 weeks for nitrosourea, mitomycin and monoclonal antibodies).
  • Focal radiotherapy within 4 weeks prior to first dose, or full spinal radiotherapy within 3 months of first dose.
  • Unresolved toxicity greater than grade 1 from previous anti-cancer therapy or radiotherapy (excluding neurotoxicity, alopecia, ototoxicity, lymphopenia or other specifications in the eligibility criteria for this study), or incomplete recovery from previous surgery, unless agreed by Novartis and the Principal Investigator (PI) and documented.
  • Major surgery, serious illness or traumatic injury within 2 weeks of starting study therapy. Patients anticipated to require major surgery within the first 2 cycles of treatment.
  • Patients requiring a nasogastric tube for drug administration (G-tubes are permitted)
  • Impaired cardiac function
  • Pregnant or breast-feeding females
  • Impairment of gastrointestinal (GI) function or GI disease

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
76 participants (actual)

Study arms

  • Experimental
    LDE225 233mg/m2 daily dose

    Pediatric dose.

    Drug: LDE225

  • Experimental
    LDE225 372mg/m2 daily dose

    Pediatric dose.

    Drug: LDE225

  • Experimental
    LDE225 425 mg/m2 daily dose

    Pediatric dose.

    Drug: LDE225

  • Experimental
    LDE225 680 mg/m2 daily dose

    Pediatric dose.

    Drug: LDE225

  • Experimental
    LDE225 800 mg/m2 daily dose

    Adult dose

    Drug: LDE225

Interventions

  • DrugLDE225

    LDE225/sonidegib capsules were supplied to the Investigators at dose strengths of 50 mg, 100 mg, 200 mg, and 250 mg.

    Also known as: sonidegib

06

What researchers measure

Primary outcomes

  1. Number of Participants With Dose-limiting Toxicities (DLT) in Phase I

    DLT was defined as an adverse event (AE) or abnormal laboratory value assessed as unrelated to disease, disease progression, intercurrent illness, or concomitant medications. DLT included any grade 3 or 4 clinically-evident toxicity, Hematology: ≥ CTCAE grade 3 neutropenia (ANC \<1.0x10\^9/L); ≥ CTCAE grade 3 thrombocytopenia (platelets \<50x10\^9/L); ≥ CTCAE grade 3 anemia (Hgb \<80 g/L); Febrile neutropenia (ANC \<1x10\^9/L, fever ‡ 38.5°C), Renal: ≥ CTCAE grade 3 serum creatinine (\>3xULN), Hepatic: ≥ CTCAE grade 3 total bilirubin (\>3xULN); ≥ 10xULN ALT elevation; grade 2 total bilirubin (\>1.5ULN) together with ≥ grade 3 ALT elevation (\>5xULN), Cardiac: ≥ CTCAE grade 3, Other AEs: ≥ CTCAE grade 3 vomiting or nausea despite optimal antiemetic therapy, diarrhea despite optimal antidiarrheal treatment.

    Time frame: Baseline, End of dose escalation part (Day 42)

  2. Maximum Tolerated Dose (MTD) of Sonidegib for Prolonged Use

    MTD was defined as highest dose level for which no more than 1 participant in a dose cohort experienced dose-limiting toxicity (DLT), based on Bayesian logistic regression model (BLRM) employing the escalation with overdose control (EWOC) principle. DLT was defined as an adverse event (AE) or abnormal laboratory value assessed as unrelated to disease, disease progression, intercurrent illness, or concomitant medications.k

    Time frame: Baseline, End of dose escalation part (Day 42)

  3. Percentage of Participants With Objective Response Rate (ORR) by Treatment

    The tumor response to the sonidegib treatment was measured by ORR. The ORR was defined as the percentage of participants with partial response or complete response as their best overall response. Participants with stable disease, progressive disease tumor assessment were considered as non-responders. Response evaluation criteria was gadolinium chelate-enhanced brain tumor magnetic resonance imaging (Gd-MRI) for Medulloblastoma and central nervous system (CNS) tumors and response evaluation criteria in solid tumors (RECIST) version 1.0 for non-CNS tumors assessed by MRI. Complete Response (CR), Progressive Disease (PD) and Incomplete Response/Stable Disease (SD) were defined as disappearance of all non-target lesions, unequivocal progression of existing non-target lesions and Neither CR nor PD, respectively.

    Time frame: Baseline, Day 28 of Cycle 2, End of treatment (Within 14 days of last dose)

Secondary outcomes

  1. Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Treatment Related AEs and Death During the Study

    An AE was defined as any unfavorable and unintended sign, symptom, or disease temporally associated with the use of study drug, whether or not related to study drug. A SAE was defined as an event which was fatal or life threatening, required or prolonged hospitalization, was significantly or permanently disabling or incapacitating, constituted a congenital anomaly or a birth defect, or encompassed any other clinically significant event that could jeopardize the participant or require medical or surgical intervention to prevent one of the aforementioned outcomes. Treatment related AEs were defined as AEs that were suspected to be related to study treatment as per investigator. On-treatment deaths were deaths which occurred up to 30 days after last date of study treatment.

    Time frame: Baseline (start of study treatment) up to End of treatment (Within 14 days of last dose)

  2. Area Under the Drug Concentration Time Curve From Time Zero to 24 Hours After Dosing (AUC0-24h) of Sonidegib in Phase I

    AUC(0-24h) was defined as the area under the drug concentration time curve calculated using linear trapezoidal summation from time zero to 24 hours after dosing.

    Time frame: Pre-dose, 0.5, 1, 2, 4, 7 hours (± 15 min) post-dose at Day 1 and Day 22 of Cycle 1

  3. Time to Reach Maximum Observed Plasma Concentration (Tmax) of Sonidegib in Phase I

    Tmax was defined as the time required to reach maximum observed plasma concentration. Tmax was directly determined from the raw plasma concentration time data.

    Time frame: Pre-dose, 0.5, 1, 2, 4, 7 hours (± 15 min) post-dose at Day 1 and Day 22 of Cycle 1

  4. Maximum Observed Plasma Concentration (Cmax) of Sonidegib in Phase I

    Maximum observed plasma concentration following drug administration was calculated from the raw plasma concentration time data.

    Time frame: Pre-dose, 0.5, 1, 2, 4, 7 hours (± 15 min) post-dose at Day 1 and Day 22 of Cycle 1

  5. Percentage of Pediatric Participants With Objective Response Rate (ORR) by Hedgehog (Hh) Signaling Pathway Status

    ORR was determined in the participants with mutations on Hh gene (Hh positive) and the participants without mutations on Hh gene (Hh negative).

    Time frame: Baseline, Day 28 of Cycle 2, End of treatment (Within 14 days of last dose)

  6. Duration of Response by Treatment

    Duration of overall response (complete response (CR) or partial response (PR)) was calculated for those participants whose best overall response was CR or PR. The start date was the date of the first documented tumor response (CR or PR) and the end date was the date of the event defined as the first documented progression or death due to underlying cancer or after the same treatment line. If a participant did not have a progression or death, the duration of response was censored at the date of last adequate tumor assessment in that treatment line.

    Time frame: Baseline, Day 28 of Cycle 2, End of treatment (Within 14 days of last dose)

07

Results

Posted Mar 2, 2016
Limitations and caveats
The Phase I and Phase II patients are pooled and summarized by dose levels. One pediatric patient enrolled in the Phase II portion at the 680 mg/m2 dose was pooled with 21 pediatric patients enrolled in Phase I at the same dose

Participant flow

The study was conducted at 14 centers in 6 countries.

Phase I
Participant flow — Phase I
MilestonePediatric Participants, LDE225 233 mg/m^2Pediatric Participants, LDE225 372 mg/m^2Pediatric Participants, LDE225 425 mg/m^2Pediatric Participants, LDE225 680 mg/m^2Adult Participants, LDE225 800 mg
Started111611210
Completed377100
Not completed894110
Withdrew: Protocol violation03110
Withdrew: Adverse event22170
Withdrew: Administrative problems10000
Withdrew: Withdrawal by subject00100
Withdrew: Disease progression54130
Phase II
Participant flow — Phase II
MilestonePediatric Participants, LDE225 233 mg/m^2Pediatric Participants, LDE225 372 mg/m^2Pediatric Participants, LDE225 425 mg/m^2Pediatric Participants, LDE225 680 mg/m^2Adult Participants, LDE225 800 mg
Started000116
Completed00005
Not completed000111
Withdrew: Protocol violation00001
Withdrew: Adverse event00002
Withdrew: Disease progression00018

Outcome measures

PrimaryNumber of Participants With Dose-limiting Toxicities (DLT) in Phase I

DLT was defined as an adverse event (AE) or abnormal laboratory value assessed as unrelated to disease, disease progression, intercurrent illness, or concomitant medications. DLT included any grade 3 or 4 clinically-evident toxicity, Hematology: ≥ CTCAE grade 3 neutropenia (ANC \<1.0x10\^9/L); ≥ CTCAE grade 3 thrombocytopenia (platelets \<50x10\^9/L); ≥ CTCAE grade 3 anemia (Hgb \<80 g/L); Febrile neutropenia (ANC \<1x10\^9/L, fever ‡ 38.5°C), Renal: ≥ CTCAE grade 3 serum creatinine (\>3xULN), Hepatic: ≥ CTCAE grade 3 total bilirubin (\>3xULN); ≥ 10xULN ALT elevation; grade 2 total bilirubin (\>1.5ULN) together with ≥ grade 3 ALT elevation (\>5xULN), Cardiac: ≥ CTCAE grade 3, Other AEs: ≥ CTCAE grade 3 vomiting or nausea despite optimal antiemetic therapy, diarrhea despite optimal antidiarrheal treatment.

Time frame:
Baseline, End of dose escalation part (Day 42)
Reported as:
Number · participants
Number of Participants With Dose-limiting Toxicities (DLT) in Phase I
participantsPediatric Participants, LDE225 233 mg/m^2Pediatric Participants, LDE225 372 mg/m^2Pediatric Participants, LDE225 425 mg/m^2Pediatric Participants, LDE225 680 mg/m^2
Number of Participants With Dose-limiting Toxicities (DLT) in Phase I0100
PrimaryMaximum Tolerated Dose (MTD) of Sonidegib for Prolonged Use

MTD was defined as highest dose level for which no more than 1 participant in a dose cohort experienced dose-limiting toxicity (DLT), based on Bayesian logistic regression model (BLRM) employing the escalation with overdose control (EWOC) principle. DLT was defined as an adverse event (AE) or abnormal laboratory value assessed as unrelated to disease, disease progression, intercurrent illness, or concomitant medications.k

Time frame:
Baseline, End of dose escalation part (Day 42)
Reported as:
Number · mg/m^2
Maximum Tolerated Dose (MTD) of Sonidegib for Prolonged Use
mg/m^2All Participants
Maximum Tolerated Dose (MTD) of Sonidegib for Prolonged Use680
SecondaryNumber of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Treatment Related AEs and Death During the Study

An AE was defined as any unfavorable and unintended sign, symptom, or disease temporally associated with the use of study drug, whether or not related to study drug. A SAE was defined as an event which was fatal or life threatening, required or prolonged hospitalization, was significantly or permanently disabling or incapacitating, constituted a congenital anomaly or a birth defect, or encompassed any other clinically significant event that could jeopardize the participant or require medical or surgical intervention to prevent one of the aforementioned outcomes. Treatment related AEs were defined as AEs that were suspected to be related to study treatment as per investigator. On-treatment deaths were deaths which occurred up to 30 days after last date of study treatment.

Time frame:
Baseline (start of study treatment) up to End of treatment (Within 14 days of last dose)
Reported as:
Number · participants
Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Treatment Related AEs and Death During the Study
participantsPediatric Participants, LDE225 233 mg/m^2Pediatric Participants, LDE225 372 mg/m^2Pediatric Participants, LDE225 425 mg/m^2Pediatric Participants, LDE225 680 mg/m^2Adult Participants, LDE225 800 mg
AEs1116112216
AEs suspected to be drug related81391413
AEs leading to discontinuation11113
On-treatment deaths22182
SAEs584145
SecondaryArea Under the Drug Concentration Time Curve From Time Zero to 24 Hours After Dosing (AUC0-24h) of Sonidegib in Phase I

AUC(0-24h) was defined as the area under the drug concentration time curve calculated using linear trapezoidal summation from time zero to 24 hours after dosing.

Time frame:
Pre-dose, 0.5, 1, 2, 4, 7 hours (± 15 min) post-dose at Day 1 and Day 22 of Cycle 1
Reported as:
Mean · nanograms*hours/millilitres (ng*hr/mL)
Area Under the Drug Concentration Time Curve From Time Zero to 24 Hours After Dosing (AUC0-24h) of Sonidegib in Phase I
nanograms*hours/millilitres (ng*hr/mL)Pediatric Participants, LDE225 233 mg/m^2Pediatric Participants, LDE225 372 mg/m^2Pediatric Participants, LDE225 425 mg/m^2Pediatric Participants, LDE225 680 mg/m^2
Cycle 1/Day 1 (n=11, 15, 11, 19)1981.56 ± 736.9282194.29 ± 1592.3965309.44 ± 3247.0885117.61 ± 2658.133
Cycle 1/Day 22 (n=9, 14, 9, 15)10589.53 ± 4163.19215431.43 ± 10433.3517753.32 ± 11551.5732622.67 ± 11670.63
SecondaryTime to Reach Maximum Observed Plasma Concentration (Tmax) of Sonidegib in Phase I

Tmax was defined as the time required to reach maximum observed plasma concentration. Tmax was directly determined from the raw plasma concentration time data.

Time frame:
Pre-dose, 0.5, 1, 2, 4, 7 hours (± 15 min) post-dose at Day 1 and Day 22 of Cycle 1
Reported as:
Median · hours
Time to Reach Maximum Observed Plasma Concentration (Tmax) of Sonidegib in Phase I
hoursPediatric Participants, LDE225 233 mg/m^2Pediatric Participants, LDE225 372 mg/m^2Pediatric Participants, LDE225 425 mg/m^2Pediatric Participants, LDE225 680 mg/m^2
Cycle 1/Day 1 (n=11, 15, 10, 17)3.98 (1.07 to 6.75)2.03 (1 to 7)2.92 (0.5 to 7)2.08 (1 to 4.08)
Cycle 1/Day 22 (n=9, 12, 9, 15)1.98 (1 to 7)2.06 (0.95 to 4.25)2 (0.67 to 7)2 (0 to 7.05)
SecondaryMaximum Observed Plasma Concentration (Cmax) of Sonidegib in Phase I

Maximum observed plasma concentration following drug administration was calculated from the raw plasma concentration time data.

Time frame:
Pre-dose, 0.5, 1, 2, 4, 7 hours (± 15 min) post-dose at Day 1 and Day 22 of Cycle 1
Reported as:
Mean · nanograms/millitres(ng/mL)
Maximum Observed Plasma Concentration (Cmax) of Sonidegib in Phase I
nanograms/millitres(ng/mL)Pediatric Participants, LDE225 233 mg/m^2Pediatric Participants, LDE225 372 mg/m^2Pediatric Participants, LDE225 425 mg/m^2Pediatric Participants, LDE225 680 mg/m^2
Cycle 1/Day 1 (n=11, 15, 10, 17)191.18 ± 82.464246.39 ± 211.034642.5 ± 486.709618.88 ± 403.466
Cycle 1/Day 22 (n=9, 12, 9, 15)769.22 ± 496.021944.17 ± 553.3951122 ± 736.8621930 ± 677.949
SecondaryPercentage of Pediatric Participants With Objective Response Rate (ORR) by Hedgehog (Hh) Signaling Pathway Status

ORR was determined in the participants with mutations on Hh gene (Hh positive) and the participants without mutations on Hh gene (Hh negative).

Time frame:
Baseline, Day 28 of Cycle 2, End of treatment (Within 14 days of last dose)
Reported as:
Number · % pediatric Hh + responders
Percentage of Pediatric Participants With Objective Response Rate (ORR) by Hedgehog (Hh) Signaling Pathway Status
% pediatric Hh + respondersPediatric Participants
Percentage of Pediatric Participants With Objective Response Rate (ORR) by Hedgehog (Hh) Signaling Pathway Status66.7
SecondaryDuration of Response by Treatment

Duration of overall response (complete response (CR) or partial response (PR)) was calculated for those participants whose best overall response was CR or PR. The start date was the date of the first documented tumor response (CR or PR) and the end date was the date of the event defined as the first documented progression or death due to underlying cancer or after the same treatment line. If a participant did not have a progression or death, the duration of response was censored at the date of last adequate tumor assessment in that treatment line.

Time frame:
Baseline, Day 28 of Cycle 2, End of treatment (Within 14 days of last dose)
Reported as:
Median · months
Duration of Response by Treatment
monthsPediatric Participants, LDE225 233 mg/m^2Pediatric Participants, LDE225 372 mg/m^2Pediatric Participants, LDE225 425 mg/m^2Pediatric Participants, LDE225 680 mg/m^2Adult Participants, LDE225 800 mg
Duration of Response by Treatment—7 (7 to 7)8.1 (8.1 to 8.1)—4.86 (4.6 to 8.7)
PrimaryPercentage of Participants With Objective Response Rate (ORR) by Treatment

The tumor response to the sonidegib treatment was measured by ORR. The ORR was defined as the percentage of participants with partial response or complete response as their best overall response. Participants with stable disease, progressive disease tumor assessment were considered as non-responders. Response evaluation criteria was gadolinium chelate-enhanced brain tumor magnetic resonance imaging (Gd-MRI) for Medulloblastoma and central nervous system (CNS) tumors and response evaluation criteria in solid tumors (RECIST) version 1.0 for non-CNS tumors assessed by MRI. Complete Response (CR), Progressive Disease (PD) and Incomplete Response/Stable Disease (SD) were defined as disappearance of all non-target lesions, unequivocal progression of existing non-target lesions and Neither CR nor PD, respectively.

Time frame:
Baseline, Day 28 of Cycle 2, End of treatment (Within 14 days of last dose)
Reported as:
Number · Percentage of participants
Percentage of Participants With Objective Response Rate (ORR) by Treatment
Percentage of participantsPediatric ParticipantsAdult Participants
Complete response3.312.5
Partial response06.3
Stable disease8.337.5
Progressive disease76.737.5
Objective response rate3.318.8

Adverse events

Collected over Adverse Events are collected from First Participant First Visit (FPFV) until Last Participant Last Visit (LPLV), Week 73. All Adverse events are reported in this record from First Participant First Treatment until LPLV, Week 73.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pediatric Participants, LDE225 233 mg/m^2—5/11 (45.5%)11/11 (100%)
Pediatric Participants, LDE225 372 mg/m^2—8/16 (50%)16/16 (100%)
Pediatric Participants, LDE225 425 mg/m^2—4/11 (36.4%)11/11 (100%)
Pediatric Participants, LDE225 680 mg/m^2—14/22 (63.6%)21/22 (95.5%)
Adult Participants, LDE225 800 mg—5/16 (31.3%)16/16 (100%)
Most frequent serious events
Showing 10 of 55
Most frequent serious events
EventPediatric Participants, LDE225 233 mg/m^2Pediatric Participants, LDE225 372 mg/m^2Pediatric Participants, LDE225 425 mg/m^2Pediatric Participants, LDE225 680 mg/m^2Adult Participants, LDE225 800 mg
VomitingGastrointestinal disorders1/110/161/114/220/16
HeadacheNervous system disorders1/112/161/114/220/16
ConvulsionNervous system disorders0/111/160/113/220/16
General Physical Health DeteriorationGeneral disorders1/112/160/110/220/16
Blood Creatine Phosphokinase IncreasedInvestigations0/110/160/110/222/16
Vision BlurredEye disorders1/110/160/110/220/16
DysphagiaGastrointestinal disorders0/110/161/110/221/16
PainGeneral disorders0/110/160/112/220/16
PyrexiaGeneral disorders0/110/161/110/220/16
PneumoniaInfections and infestations0/110/161/110/220/16
Most frequent other events
Showing 10 of 220
Most frequent other events
EventPediatric Participants, LDE225 233 mg/m^2Pediatric Participants, LDE225 372 mg/m^2Pediatric Participants, LDE225 425 mg/m^2Pediatric Participants, LDE225 680 mg/m^2Adult Participants, LDE225 800 mg
VomitingGastrointestinal disorders5/119/167/1115/222/16
HeadacheNervous system disorders6/117/164/119/222/16
Blood Creatine Phosphokinase IncreasedInvestigations1/111/162/116/228/16
NauseaGastrointestinal disorders5/114/163/118/224/16
FatigueGeneral disorders5/117/163/116/221/16
Muscle SpasmsMusculoskeletal and connective tissue disorders2/114/165/112/224/16
CoughRespiratory, thoracic and mediastinal disorders3/111/165/111/223/16
ConstipationGastrointestinal disorders1/116/164/113/222/16
Pain In ExtremityMusculoskeletal and connective tissue disorders2/116/164/110/220/16
AnaemiaBlood and lymphatic system disorders0/112/164/112/220/16

Baseline characteristics

The analysis was performed in full analysis set population, defined as all the participants who received at least one dose of sonidegib.

Age, Customized
Age, Customized(participants)Pediatric Participants, LDE225 233 mg/m^2Pediatric Participants, LDE225 372 mg/m^2Pediatric Participants, LDE225 425 mg/m^2Pediatric Participants, LDE225 680 mg/m^2Adult Participants, LDE225 800 mgTotal
≤ 10 years43511023
>10 years to 17 years713611037
18-65 years00001616
Sex: Female, Male
Sex: Female, Male(Participants)Pediatric Participants, LDE225 233 mg/m^2Pediatric Participants, LDE225 372 mg/m^2Pediatric Participants, LDE225 425 mg/m^2Pediatric Participants, LDE225 680 mg/m^2Adult Participants, LDE225 800 mgTotal
Female46310730
Male710812946
08

Study locations

14 sites
  • Children's Healthcare of Atlanta Childern Hosp - ATL
    Atlanta, Georgia 30342, United States
  • Sidney Kimmel Comprehensive Cancer Center/Johns Hopkins Med. John Hopkins
    Baltimore, Maryland 21231, United States
  • Dana Farber Cancer Institute DFCI (3)
    Boston, Massachusetts 02115, United States
  • Seattle Children's Hospital CPKC412A2114
    Seattle, Washington 98105, United States
  • Novartis Investigative Site
    Parkville, Victoria 3052, Australia
  • Novartis Investigative Site
    Toronto, Ontario M5G 1X8, Canada
  • Novartis Investigative Site
    Toronto, Ontario M5G 2M9, Canada
  • Novartis Investigative Site
    Paris, 75231, France
  • Novartis Investigative Site
    Villejuif Cedex, 94805, France
  • Novartis Investigative Site
    Bologna, BO 40139, Italy
  • Novartis Investigative Site
    Milano, MI 20133, Italy
  • Novartis Investigative Site
    Roma, RM 00168, Italy
  • Novartis Investigative Site
    Sutton, Surrey SM2 5PT, United Kingdom
  • Novartis Investigative Site
    Newcastle Upon Tyne, NE1 4LP, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2011, a primary completion of Oct 2014 and a completion of Oct 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2016, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2010
First posted
May 18, 2010
Start
Feb 2011
Primary completionActual
Oct 2014
CompletionActual
Oct 2014
Results first posted
Mar 2, 2016
Last update
Mar 20, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 20, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01125800
Responsible party
Sponsor
First posted
May 18, 2010
Start date
Feb 2011
Primary completion
Oct 2014
Completion
Oct 2014
Results posted
Mar 2, 2016
Last update
Mar 20, 2017

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sonidegib

Start the discussion